DOCSLIB.ORG

Medical Cannabis Around the World Mag.Indd

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Medical Cannabis Around the World Mag.Indd A HANDBOOK GUIDE ANALYZING MEDICAL CANNABIS REGIMES, AND THEIR IMPACTS. CONTENTS QUALITY ISSUES 2 Introduction ISSUE 1: Quality Issues 3 PRODUCT QUALITY • Issue 1: Product quality 4 Comparing• Issue Overseas 2: Contaminants Jurisdictions 5 and/or raw cannabis. At the most expensive end of the spectrum are the pharmaceutical GMP (Good AManufacturing key consideration Practice) that allstandards, jurisdictions as adhered face is de�ining to by GW an Pharma,acceptable the quality manufacturers standard forof Sativex;cannabis the products Dutch company Bedrocan; and top tier Canadian manufacturers who have recently attained or are pursuing these • Scoring System 6 of time and money to attain. It is the standard most closely aligned with our current pharmaceutical model. A patchwork of state successes, hampered by federal law. standards,However, the such impact as Tilray, on the CanniMed cost to patients and Canopy is immense. Growth. The GMP standard requires a signi�icant investment The United States: 7 At the other end of the scale, as an early legaliser of medical cannabis, California initially had no product standards for its medical regime, allowing dangerous pesticides and plant growth regulators to be used. • California: First to reform 8 However, decent product standards were recently enacted via the adult use law in California. • Alabama: CBD only 9 As a compromise solution, Canada has set up a regime known as GPP (Good Production Practices) [1], where products are made to a high standard. Under GPP, variation between batches based on the potency of the • Arizona: Massive patient uptake 10 costs, as batches that vary in potency no longer need to be discarded. Multiple products made to this GPP United Kingdom: Hypocrisy abounds 11 plantsstandard is haveallowed, been so accepted long as and each approved batch is for labelled individual accurately. patients This in New has Zealand.enormous We bene�its term this for standard production ‘near pharmaceutical’. Israel: Powerhouse of research 12 Canada: Exporter extraordinaire 14 Many American states set safety standards for products in lieu of de�ining an industry standard regime. The Australia:MCANZ’s Comprehensive Cart before the horseSolution 15 safety standards de�ine tolerable levels of contaminants to ensure that the product is safe to consume, without demanding proof of ef�icacy. References 16 Pharmaceutical Near Pharmaceutical INTRODUCTION Cannabis remains a prohibited drug throughout much of the world. However, countries throughout Food Grade the developed world are grappling with how to regulate medical cannabis and the compromises that must be made to ensure patient access. This guide is designed to inform the public on the various regimes that have been set up worldwide, and the positive and negative aspects of each. Despite the growing pool of countries that have regulated medical cannabis, there is no consensus on which method offers a gold standard for other countries to follow. Even at an international level, QUALITY there has been a lack of discussion of this burning issue. The United Nations General Assembly Special Session (UNGASS) on the “world drug problem” in 2016 was effectively silent on the issue. It should be noted that at the international level, medical cannabis is not prohibited. The 1961 Single Convention on Narcotic Drugs restricts medical research and use, but does not ban it. In effect, until very recently, most countries banned medical use despite the fact that it has been allowed under international treaties since 1961. 3 2 MCANZ: Medical Cannabis Around the World - mcanz.org.nz/ ISSUE 2: CONTAMINANTS COMPARING OVERSEAS JURISDICTIONS Scoring system pesticides and other additives; moulds and associated toxins; and heavy metals. There are three types of contaminants that can be a cause for concern with cannabis: In order to compare different overseas medical cannabis regimes, we propose the following scoring Pesticides and other addititives system by which to compare different jurisdictions. Each jurisdiction is given a score between 0 and 5 for the following parameters, with a score of 5 being optimal. When cannabis is cultivated on a larger scale, there is an increased risk of pest infestations such as spider mites. While a personal grower with a handful of plants can generally keep Prescriber freedom: This score represents the potential barriers that prescribers face, either on top of such things, larger operations, such as the enormous greenhouses currently from regulations or from formal medical bodies, and the level of support and education provided to being put into production, can much more easily harbour an infestation. To combat this, prospective prescribers to ensure that they feel comfortable to prescribe as appropriate. some commercial growers turn to pesticides. There are some pesticides that are safe to use on cannabis; however most are not, particularly due to the breakdown of the chemicals Patient access: This speaks to the cost to the patient and the range of options available to patients once cannabis is heated and inhaled. [2] through legal channels. Every patient has different preferences, whether it is oil capsules or raw dried cannabis to be used with a vaporiser. One pesticide that should be banned for use on cannabis is myclobutanil, which is freely available in New Zealand. It is banned in most medical cannabis jurisdictions, as when Product quality: The various states and nations that have implemented medical cannabis regimes have on price for patients. Set the standards too high, and businesses struggle, costs remain high, Mouldsheated under and associated�lame it degrades toxins to hydrogen cyanide. haveand patients all been are forced left resortingto confront to thethe issueblack ofmarket product as before.quality Setand the the standards impact that too quality low, and standards patient safety is put at risk. succumb to mould if grown in damp conditions. Some types of mould give off toxins that Cannabis �lowers, which harbour the plant’s concentrated medicinal compounds, can posecause a liver harm damage) to health. [3]. Aspergillus moulds, The mould-susceptibility for example, of cannabis give meansoff ochratoxin that the (alargest suspected legal carcinogenmedicinal cannabis which is producers toxic to thetend kidneys) to cultivate and either a�latoxin indoors (a orknown in high-tech carcinogen greenhouses, that can in order to control the variables that allow moulds to develop. This is in stark contrast to Support for research: Various countries have regulations that either support or inhibit research. opium poppies, which are hardy in comparison and lend themselves to massive outdoor The ability for private companies and universities to conduct research is critical to furthering our knowledge on cannabis, both medically and otherwise. based medicines. �ields. This is why cannabis-based products are likely to always cost more than opium- Industry development: How supportive is the regime of industry development? Is there competition Heavy metals and innovation? What is the bar for entry to newcomers? Cannabis is a bioaccumulator, and in fact, industrial hemp has been researched and trialled Diversion: As with other drugs such as opioids, some people may try to game the system and soils. This novel property of cannabis may not be as problematic in New Zealand as it is in widespread diversion could be within a regulatory regime, and what controls the regulators have for site remediation bene�its such as removing heavy metal contaminants like lead from receiveover this. prescriptions for conditions that are not genuine. This criterion assesses how frequent and environmental exploitation is more likely to accumulate high levels of lead or cadmium, otherposing post-industrial a severe health countries. risk. The Forrisk example, on many hempNew Zealand grown in soils a country is likely with to be a historylower; but of risks can still exist here based on land use, including past use of agrichemicals. 5 4 MCANZ: Medical Cannabis Around the World - mcanz.org.nz/ THE UNITED STATES: CALIFORNIA: A PATCHWORK OF STATE SUCCESSES, HAMPERED BY FEDERAL LAW FIRST TO REFORM Currently, 29 of the 50 US states have legal medical cannabis regimes. However, these regimes are constrained in some ways by a prohibitionist federal law. Proposition 215, the Compassionate Use Act, passed with 56% of the vote. The bill allowed for the Californiause, possession �irst andintroduced cultivation medical of cannabis cannabis on ain physician’s 1996, after recommendation a voter-initiated for referendumpatients with called a list At the federal level, in the United States cannabis is a Schedule 1 controlled drug. Schedule 1 is of severe conditions, as well as including the catch-all clause, “any other illness for which marijuana designated for drugs that have a high potential for abuse and no accepted therapeutic purpose. This provides relief”. is an archaic designation as far as cannabis is concerned. To compare, methamphetamine, which is available on prescription, is Schedule 2. Because this bill was so early, there were large holes in the regulations. Initially, there were no Various attempts have been made to reschedule cannabis through the US courts. To date, many court decisions have accepted that cannabis does not belong in Schedule One, but the courts haven’t qualityuse cannabis standards bill. set for medical cannabis, as it was not intended for commercial production to had jurisdiction to force the Drug Enforcement Agency to reschedule. occur. The lack of quality standards was remedied two decades later with the passing of the adult Because of the federal scheduling, many state regulations get around doctors prescribing cannabis by stipulating that doctors can instead “recommend” cannabis to patients. This impacts on patients, California’s product range, price and quality control is now going from strength to strength. However, in that prescribers are constrained from providing advice and support and directing patients someAn additional regulations concern are now until squeezing recently out was the the smaller, access longer-established process; a single medical10-minute growers.
Load more

Recommended publications
  • The Effect of Medical Marijuana Laws on the Labor Supply of Older Adults: Evidence from the Health and Retirement Study
    DISCUSSION PAPER SERIES IZA DP No. 10489 The Effect of Medical Marijuana Laws on the Labor Supply of Older Adults: Evidence from the Health and Retirement Study Lauren Hersch Nicholas Johanna Catherine Maclean JANUARY 2017 DISCUSSION PAPER SERIES IZA DP No. 10489 The Effect of Medical Marijuana Laws on the Labor Supply of Older Adults: Evidence from the Health and Retirement Study Lauren Hersch Nicholas Johns Hopkins University Johanna Catherine Maclean Temple University, NBER and IZA JANUARY 2017 Any opinions expressed in this paper are those of the author(s) and not those of IZA. Research published in this series may include views on policy, but IZA takes no institutional policy positions. The IZA research network is committed to the IZA Guiding Principles of Research Integrity. The IZA Institute of Labor Economics is an independent economic research institute that conducts research in labor economics and offers evidence-based policy advice on labor market issues. Supported by the Deutsche Post Foundation, IZA runs the world’s largest network of economists, whose research aims to provide answers to the global labor market challenges of our time. Our key objective is to build bridges between academic research, policymakers and society. IZA Discussion Papers often represent preliminary work and are circulated to encourage discussion. Citation of such a paper should account for its provisional character. A revised version may be available directly from the author. IZA – Institute of Labor Economics Schaumburg-Lippe-Straße 5–9 Phone: +49-228-3894-0 53113 Bonn, Germany Email: [email protected] www.iza.org IZA DP No. 10489 JANUARY 2017 ABSTRACT The Effect of Medical Marijuana Laws on the Labor Supply of Older Adults: Evidence from the Health and Retirement Study* We study the effect of state medical marijuana laws on labor supply among older adults; the demographic group with the highest rates of many health conditions for which marijuana may be an effective treatment.
    [Show full text]
  • Round Table: Legalized Marijuana
    ROUND TABLE Legalized Marijuana June 5 2018 Table of Contents Opening Letter…………………………………………………………………………………………………………………….pg 2 Cannabis Legalization (official release from the Government of Ontario)……………………………..pg 3 Scripture Used to Support Marijuana Use…………………………………………………………………………….pg 7 Scripture Used to Oppose Marijuana Use…………………………………………………………………………….pg 9 The Medical Side of Things………………………………………………………………………………………………..pg 11 When Pot is Legal, What Do We Say?.................................................................................................pg 16 Can Cannabis and Christ Co-exist?.......................................................................................................pg 20 Marijuana to the Glory of God?.............................................................................................................pg 25 Questions to Wrestle Through…………………………………………………………………………………………..pg 29 1 219 Talbot St E Leamington ON N8H 3V6 Tel: 519.326.3605 www.meadowbrook.ca Hello everyone! On Tuesday, June 5th 2018 at 7pm, we will be having a round-table discussion about the legalization of marijuana, which is coming to Canada soon. How do we grapple with this and approach it as Christians, as parents, as a church? We wanted to take some time to get together and talk about the issue. We are not gathering on this night to argue, or to craft an official policy, or to solve the matter once and for all. This will be an ongoing conversation for all of us, requiring prayer and careful thought, and it is likely not going to be
    [Show full text]
  • Religious Use of Marijuana Cases
    Summaries of Religious Use of Marijuana Cases Alabama regulate was conceivable, only that none had Rheuark v. State (1992) 601 So.2d 135 been proposed. Statutes prohibiting possession of marijuana and controlled substances did not violate freedom of California: religion rights of defendant claiming that he People v. Mullins (1975) 50 Cal. App 3d 61 worshipped plants as gods and used marijuana Facts: A deputy sheriff had gone to defendant's and psilocybin as religious practice. premises at night at the invitation of a man who Court compared Defendant’s argument to a past lived in a teepee on the property and who had told ruling on polygamy and quoting the cases the officer there were marijuana plants growing Reynolds v. United State 98 U.S. 145 and there. The officer took two plants as samples to Cleveland v. United States 329 U.S. 14 which in be tested and, three days later, went back to the sum says that morality is defined by statute and property with a search warrant. Defendant's Congress and not the individual’s perceptions of property is not enclosed or surrounded by a morality. Therefore because the possession of fence. From Ten Mile Creek Road there is a marijuana is unlawful, it doesn’t matter that the driveway that leads onto defendant's property. Defendant used it for religious use. There is no gate at the entrance to the property. At the entrance there is a sign reading “Universal Arizona: Life Church of Christ Light.” Defendant's wife People v. Hardesty (2009) 214 P.3d 1004 testified that on and prior to May 30, 1972, there FACTS: Hardesty was driving his van at night was a “no trespassing” sign at the entrance to the when an officer stopped him because one property; that a church known as “Universal Life headlight was out.
    [Show full text]
  • Marijuana in the Workplace: Guidance for Occupational Health Professionals and Employers
    ACOEM GUIDELINES Marijuana in the Workplace: Guidance for Occupational Health Professionals and Employers Joint Guidance Statement of the American Association of Occupational Health Nurses and the American College of Occupational and Environmental Medicine Jennan A. Phillips, PhD, MSN, RN, Michael G. Holland, MD, Debra D. Baldwin, NP-C, PhD, Linda Gifford Meuleveld, RN, COHN-S, CCM, CPDM, Kathryn L. Mueller, MD, MPH, Brett Perkison, MD, MPH, Mark Upfal, MD, MPH, and Marianne Dreger, MA arijuana (cannabis) is the most fre- tions require an assessment of the safety of adequate study. Other articles are also cited M quently used illicit drug of abuse in marijuana use by the American workforce. when appropriate to clarify issues that may the United States and worldwide. Moreover, Although studies have suggested that mari- not have been addressed by studies qualify- it is second only to alcohol as the most preva- juana may be used with reasonable safety in ing as evidence. lent psychoactive substance seen in cases of some controlled environments, there are po- 1,2 driving under the influence of drugs. It is tential workplace consequences involved in LEGAL IMPLICATIONS OF also by a wide margin, the drug most of- its use that warrant scrutiny and concern. ten detected in workplace drug-testing pro- The potential consequences of mari- MARIJUANA LEGISLATION grams. The primary psychoactive substance juana use in the workplace include the risk In late 2009, the US Department of in marijuana is delta-9-tetrahydrocannabinol, and associated cost of adverse events and Justice initiated a change in marijuana en- known simply as THC.
    [Show full text]
  • The Effect of Medical Marijuana Laws on the Labor Supply of Older Adults: Evidence from the Health and Retirement Study
    A Service of Leibniz-Informationszentrum econstor Wirtschaft Leibniz Information Centre Make Your Publications Visible. zbw for Economics Hersch Nicholas, Lauren; Maclean, J. Catherine Working Paper The Effect of Medical Marijuana Laws on the Labor Supply of Older Adults: Evidence from the Health and Retirement Study IZA Discussion Papers, No. 10489 Provided in Cooperation with: IZA – Institute of Labor Economics Suggested Citation: Hersch Nicholas, Lauren; Maclean, J. Catherine (2017) : The Effect of Medical Marijuana Laws on the Labor Supply of Older Adults: Evidence from the Health and Retirement Study, IZA Discussion Papers, No. 10489, Institute of Labor Economics (IZA), Bonn This Version is available at: http://hdl.handle.net/10419/161112 Standard-Nutzungsbedingungen: Terms of use: Die Dokumente auf EconStor dürfen zu eigenen wissenschaftlichen Documents in EconStor may be saved and copied for your Zwecken und zum Privatgebrauch gespeichert und kopiert werden. personal and scholarly purposes. Sie dürfen die Dokumente nicht für öffentliche oder kommerzielle You are not to copy documents for public or commercial Zwecke vervielfältigen, öffentlich ausstellen, öffentlich zugänglich purposes, to exhibit the documents publicly, to make them machen, vertreiben oder anderweitig nutzen. publicly available on the internet, or to distribute or otherwise use the documents in public. Sofern die Verfasser die Dokumente unter Open-Content-Lizenzen (insbesondere CC-Lizenzen) zur Verfügung gestellt haben sollten, If the documents have been made available under an Open gelten abweichend von diesen Nutzungsbedingungen die in der dort Content Licence (especially Creative Commons Licences), you genannten Lizenz gewährten Nutzungsrechte. may exercise further usage rights as specified in the indicated licence. www.econstor.eu DISCUSSION PAPER SERIES IZA DP No.
    [Show full text]
  • California Medical Marijuana Recommendation Arizona Disoensary
    California Medical Marijuana Recommendation Arizona Disoensary Fearsome and thickety Jim fixing while alchemical Pablo creep her Denys bafflingly and slotting sincerely. Virginian Elwood usually vets some limning or fared foolhardily. Mind-bending Allen slates or engage some rifle full, however stilted Thor compel bareknuckle or repress. Rhode island and strong sativas strains of the state drivers license dispensary in public on medical issue your california medical marijuana recommendation arizona disoensary will complete understanding that! When visiting Oregon, you need be careful not not exceed those limits. Privately held in arizona considers chronic pain relief, medical marijuana is right of. More information maintained in kentucky with health issues involving impaired or how you with federal law is flushed with california medical marijuana recommendation arizona disoensary back to? Do you find out our customers daily due to arizona medical marijuana. If talking to a paddle about medical cannabis feels a little overwhelming, there are services available to question you refer through it could ease. We apologize for qualified condition that medical marijuana regulations, but when it probably is successful appointment on more for california medical marijuana recommendation arizona disoensary of medical? An AZ MMJ card is a bell of ID patients present at medical dispensaries to. Fresh lick of secret box, the scent is nice rich strong. The regulation and patient, and everywhere legal medical condition or use the campaign manager for california medical marijuana recommendation arizona disoensary in the forum below to obtain marijuana with. Their privacy of patients is recognized recommendations, california medical marijuana recommendation arizona disoensary or the. Id please enter the california medical marijuana recommendation arizona disoensary does recognize california.
    [Show full text]
  • Ianthus Capital Holdings, Inc
    iAnthus Capital Holdings, Inc. MANAGEMENT’S DISCUSSION AND ANALYSIS For the Three Months Ended March 31, 2019 and 2018 Management’s Discussion and Analysis For the three months ended March 31, 2019 and 2018 (In thousands of U.S. Dollars, unless stated otherwise) Company Overview iAnthus Capital Holdings, Inc. (the “Company”, or “ICH”, or “iAnthus”) is one of the largest Multi-State Operators (MSOs) in the United States, providing investors with diversified exposure to the regulated cannabis industry. We develop, own and operate, what we believe to be, the best-in-class licensed cannabis cultivation, processing and dispensary facilities and we offer our innovative branded cannabis products in the United States. Through our subsidiaries, we currently own and/or operate 21 dispensaries and 13 cultivation/processing facilities throughout the eastern and western regions of the United States and distribute our cannabis products to over 100 dispensaries. Under our existing licenses, interests and contractual arrangements, we have the capacity to own and/or operate up to 68 dispensaries and up to 15 cultivation/processing facilities, and manufacture and distribute our cannabis products in 11 states with an aggregate population of approximately 121 million. Our multi-state operations encompass the full spectrum of medical and adult-use cannabis enterprises, including cultivation, processing, product development, wholesale-distribution and retail. Our cannabis products include flower and trim, products containing cannabis flower and trim (such as pre-rolls), cannabis infused products, and products containing cannabis extracts (such as vape cartridges, concentrates, wax products, oils, tinctures, topical creams and edibles). We are an innovative leader in the burgeoning regulated cannabis industry in the United States and we are committed to creating a distinctive customer retail experience at our branded stores nationally and a portfolio of branded cannabis products recognized both in the United States and around the world.
    [Show full text]
  • Cannabis Legalization and the 14 Ps
    The American Journal of Drug and Alcohol Abuse Encompassing All Addictive Disorders ISSN: 0095-2990 (Print) 1097-9891 (Online) Journal homepage: https://www.tandfonline.com/loi/iada20 How will cannabis legalization affect health, safety, and social equity outcomes? It largely depends on the 14 Ps Beau Kilmer To cite this article: Beau Kilmer (2019): How will cannabis legalization affect health, safety, and social equity outcomes? It largely depends on the 14 Ps, The American Journal of Drug and Alcohol Abuse, DOI: 10.1080/00952990.2019.1611841 To link to this article: https://doi.org/10.1080/00952990.2019.1611841 Published online: 02 Jul 2019. Submit your article to this journal Article views: 173 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=iada20 THE AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE https://doi.org/10.1080/00952990.2019.1611841 REVIEW How will cannabis legalization affect health, safety, and social equity outcomes? It largely depends on the 14 Ps Beau Kilmer RAND Drug Policy Research Center, Santa Monica, CA, USA ABSTRACT ARTICLE HISTORY Jurisdictions considering or implementing alternatives to cannabis supply prohibition will con- Received 16 December 2018 front several decisions that will influence health, safety, and social equity outcomes. This essay Revised 18 April 2019 highlights 14 of these design considerations, which all conveniently begin with the letter P:1) Accepted 23 April 2019 Production, 2) Profit motive, 3) Power to regulate, 4) Promotion, 5) Prevention and treatment, 6) KEYWORDS Policing and enforcement, 7) Penalties, 8) Prior criminal records, 9) Product types, 10) Potency, 11) Cannabis; legalization; Purity, 12) Price, 13) Preferences for licenses, and 14) Permanency.
    [Show full text]
  • Ianthus Capital Holdings, Inc
    iAnthus Capital Holdings, Inc. MANAGEMENT’S DISCUSSION AND ANALYSIS For the Three and Nine Months Ended September 30, 2019 and 2018 Management’s Discussion and Analysis For the three and nine months ended September 30, 2019 and 2018 (In thousands of U.S. Dollars, unless stated otherwise) Company Overview iAnthus Capital Holdings, Inc. (the “Company” or “iAnthus”) is one of the largest Multi-State Operators (“MSOs”) in the United States, providing investors with diversified exposure to the regulated cannabis industry. The Company develops, owns, and operates, what it believes to be, the best-in-class licensed cannabis cultivation, processing, and dispensary facilities, and the Company offers innovative branded cannabis and cannabidiol (“CBD”) products in the United States. Through its subsidiaries, the Company currently owns and/or operates 27 dispensaries and 13 cultivation/processing facilities throughout the United States and distributes cannabis and CBD products to over 200 dispensaries and 1,500 retail stores, respectively. Under the Company’s existing licenses, interests, and contractual arrangements, the Company has the capacity to own and/or operate up to 68 dispensaries and up to 15 cultivation/processing facilities, and manufacture and/or distribute its cannabis products in 11 states with an aggregate population of approximately 121 million. Incorporated in British Columbia, Canada in 2014, the Company became the first licensed multi-state cannabis operator in the United States to publicly trade on the Canadian Securities Exchange (the “CSE”) in 2016. iAnthus’ multi-state operations encompass the full spectrum of medical and adult-use cannabis enterprises, including cultivation, processing, product development, wholesale-distribution, and retail.
    [Show full text]
  • Patient-Reported Use of Medical Cannabis for Pain, Anxiety, and Depression T Symptoms: Systematic Review and Meta-Analysis ∗ Jesse D
    Social Science & Medicine 233 (2019) 181–192 Contents lists available at ScienceDirect Social Science & Medicine journal homepage: www.elsevier.com/locate/socscimed Review article Patient-reported use of medical cannabis for pain, anxiety, and depression T symptoms: Systematic review and meta-analysis ∗ Jesse D. Kosiba , Stephen A. Maisto, Joseph W. Ditre Department of Psychology, Syracuse University, United States ARTICLE INFO ABSTRACT Keywords: Rationale: Certifications for medical cannabis are generally restricted to a small number of specific medical Medical cannabis conditions, yet patients frequently report symptoms of pain, anxiety, and depression as reasons for use. This is a Marijuana critical concern for researchers, healthcare providers, and policymakers, yet research in this area is currently Pain obstructed by the lack of a focused review or empirical synthesis on patient-reported reasons for medical can- Anxiety nabis use. Depression Objectives: AND METHOD: The first aim of this project was to conduct the first systematic review andmeta- meta-Analysis Systematic review analysis of empirical studies of patient-reported symptoms of pain, anxiety, and depression as reasons for Chronic pain medical cannabis use. The second aim was to conduct an empirical assessment of the methodological quality of extant research, test for publication bias, and test sex composition and quality scores of individual studies as possible sources of observed heterogeneity. Results: Meta-analytic results indicated that pain (64%), anxiety (50%), and depression/mood (34%) were common reasons for medical cannabis use. No evidence for publication bias was detected, despite heterogeneity in prevalence rates. A comprehensive assessment of study quality identified a number of specific methodological limitations of the existing research, including challenges in patient recruitment, use of restrictive sampling frames, and a lack of randomized recruitment methods and validated assessment measures.
    [Show full text]
  • Emerging Issues with Marijuana Legalization
    Emerging Issues With Marijuana Legalization Faye Caldwell Email: [email protected] Disclaimer: no Legal advice or attorney-client relationship This presentation has been prepared by Caldwell Everson, PLLC for informational purposes only. The information presented does not constitute legal advice and is not to be acted on as such. This information is not intended to create, and receipt of it does not establish an attorney-client relationship. By participating in this presentation you are not and do not become a client of Caldwell Everson PLLC. Any information contained herein is not intended as a substitute for legal counsel. You should not rely upon any information contained in this presentation without seeking legal advice from an attorney of your choice and who practices law in your state. © Caldwell Everson PLLC 2 As of November 29, 2018: 33 states + D.C. + 2 U.S. territories (Guam, PR) have passed Comprehensive “Medical marijuana” Laws Laws vary widely 13 other states have passed low THC/High CBD laws All passed since 2014 in mostly southern states after CNN documentary Some states with comprehensive medical marijuana laws also have CBD laws 10 states + D.C. + 1 U.S. territory (CNMI) have passed recreational marijuana laws All except US territory also had comprehensive medical marijuana laws 4 states prohibit marijuana for all purposes © Caldwell Everson PLLC (Idaho, Kansas, Nebraska, South Dakota) 3 State Medical Marijuana Laws 33 states + D.C. Alaska (1998) Maine (1999) New York (2014) Arizona (2010) Maryland (2014) North Dakota (2016) Arkansas (2016) Massachusetts (2012) Ohio (2016) California (1996) Michigan (2008) Oklahoma (2018) Colorado (2000) Minnesota (2014) Oregon (1998) Connecticut (2012) Missouri (2018) Pennsylvania (2016) Delaware (2011) Montana (2004) Rhode Island (2006) Florida (2016) Nevada (2000) Utah (2018) Hawaii (2000) New Hampshire (2013) Vermont (2004) Illinois (2013) New Jersey (2010) Washington (1998) Louisiana (2015) New Mexico (2007) West Virginia (2017) Washington, D.C.
    [Show full text]
  • Green Rush: Cannabis Market Will Grow by 9 Times by 2030 Amid
    ? June 2019 Green Rush: Cannabis Market Will Grow by 9 Times by 2030 Amid Widening Legalization Contents Cannabis stocks have delivered impressive investor returns in 2019, with many of the publicly traded 2 Key Takeaways companies soundly outperforming the broader market. Optimism has preceded actual performance as 4 Cannabis Playbook: We See Multiple Ways to Play Trends the industry has yet to generate positive free cash flow. However, unlike other emergent industries that 12 The U.S. Will Be the Largest and Fastest- have enjoyed fleeting popularity with fickle investors, the cannabis industry should realize a steep Growing Cannabis Market in the World 38 National Legalization Has Unlocked demand growth trajectory that could appeal to investors with a long-term investment horizon. The five Massive Growth for Canada industry leaders we now cover are far from burning out, with some offering attractive upside potential 50 Global Medical Cannabis Market Will as early overhead investments are harvested over time. See Huge Demand Growth but Increasing Competition 60 Cannabis Primer: How It Grows and Is Prohibition has kept cannabis largely in the hands of criminal enterprises. However, legalization is Consumed Has Implications for the gaining momentum. In the United States, 11 states and Washington, D.C., have legalized recreational Industry's Future 72 Appendix: Company Models cannabis, and 35 states have legalized medical cannabis or products that are low in tetrahydrocannabinol, or THC, and high in cannabidiol, or CBD. We expect federal legalization to take place in the U.S. by 2023. Canada legalized recreational cannabis in October 2018. Internationally, more Important Disclosure The conduct of Morningstar's analysts is governed and more countries have recognized the benefits of medical cannabis and are expanding access.
    [Show full text]